ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2022
Nomogram for Prediction of Diabetic Retinopathy Among Type 2 Diabetes Population in Xinjiang, China.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Risk prediction models for diabetic retinopathy: a systematic review.Frontiers in endocrinology · 2025Pooled it
- A three-parameter online nomogram for diabetic retinopathy risk in primary care: development and external validation in an independent cohort of type 2 diabetes.Frontiers in endocrinology · 2026Article
- A Novel Nomogram for Diabetic Retinopathy Prediction in Young and Middle-Aged Patients with Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Bioelectrical Impedance Profiling to Estimate Neuropathic and Vascular Risk in Patients with Type 2 Diabetes Mellitus.Diagnostics (Basel, Switzerland) · 2025Article
- Universal nomogram for predicting referable diabetic retinopathy: a validated model for community and ophthalmic outpatient populations using easily accessible indicators.Frontiers in endocrinology · 2025Article
- Development and external validation of a predictive model for type 2 diabetic retinopathy.Scientific reports · 2024Article
- Construction and validation of a neovascular glaucoma nomogram in patients with diabetic retinopathy after pars plana vitrectomy.World journal of diabetes · 2024Article
- Dynamic nomogram prediction model for diabetic retinopathy in patients with type 2 diabetes mellitus.BMC ophthalmology · 2023Article
- Training and External Validation of a Predict Nomogram for Type 2 Diabetic Peripheral Neuropathy.Diagnostics (Basel, Switzerland) · 2023Article
- A risk prediction model for type 2 diabetes mellitus complicated with retinopathy based on machine learning and its application in health management.Frontiers in medicine · 2023Article
- Development and validation of a diabetic retinopathy risk prediction model for middle-aged patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2023Article
- Article
- A Nomogram for Predicting the Possibility of Peripheral Neuropathy in Patients with Type 2 Diabetes Mellitus.Brain sciences · 2022Article
- Diabetic retinopathy risk prediction in patients with type 2 diabetes mellitus using a nomogram model.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To establish an accurate risk prediction model of diabetic retinopathy (DR) using cost effective and easily available patients' characteristics and clinical biomarkers. Patients and Methods: Totally 18,904 cases diagnosed type 2 diabetes mellitus (T2DM) were collected, among which 13,980 cases were selected after quality screening. The least absolute shrinkage and selection operator (LASSO) regression models were used for univariate analysis and factors selection, and the multi-factor logistic regression analysis was used to establish the prediction model. Discrimination, calibration, and clinical usefulness of the prediction model were assessed using AUC/ Harrell's C statistic, calibration plot, and decision curve analysis. Both the development group and validation group were assessed. Results: Candidate variables were selected by Lasso regression and multivariate logistic regression analysis. Finally, the candidate predictive variables were included diabetic peripheral neuropathy (DPN), age, neutrophilic granulocyte (NE), high-density lipoprotein (HDL), hemoglobin A1c (HbA1C), duration of T2DM, and glycosylated serum protein (GSP) were used to establish a nomogram model for predicting the risk of DR. In the development group, the area under the receiver operating characteristic curve (AUC) was 0.882 (95% CI, 0.875-0.888). In the validation group, the AUC was 0.870 (95% CI, 0.856-0.881). Meanwhile, the optimism-corrected Harrell's C statistic were 0.878 and 0.867 in the development group and the validation group, respectively. Decision curve analysis demonstrated that the nomogram was clinically useful. Conclusion: We constructed and verified nomograms that could accurately predict the risk of DR in T2DM patients, which could be used to predict the personalized risk of DR patients in Xinjiang, China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.